Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
about
Telomere and Telomerase Therapeutics in CancerCancer stem cells (CSCs), cervical CSCs and targeted therapiesCirculating tumor cells in germ cell tumors: are those biomarkers of real prognostic value? A reviewWhen Prostate Cancer Circulates in the BloodstreamCirculating Tumor Cells: A Window Into Tumor Development and Therapeutic EffectivenessThe promise of circulating tumor cell analysis in cancer managementCirculating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and BackChemotherapy options in castration-resistant prostate cancerEMT, CTCs and CSCs in tumor relapse and drug-resistanceUsing circulating tumor cells to inform on prostate cancer biology and clinical utility2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implicationsTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential.Circulating tumor cells in patients with metastatic castration resistant prostate cancer: exploratory findings at a tertiary referral hospital.Molecular pathways and targets in prostate cancerCytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review)CTC enumeration and characterization: moving toward personalized medicine.Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathologyCirculating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancerCategorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patientsIn vitro detection of circulating tumor cells compared by the CytoTrack and CellSearch methods.Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases.KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancerBiomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancerLiquid biopsy in cancer patients: advances in capturing viable CTCs for functional studies using the EPISPOT assay.Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.Functional studies on circulating and disseminated tumor cells in carcinoma patientsImproving sensitivity and specificity of capturing and detecting targeted cancer cells with anti-biofouling polymer coated magnetic iron oxide nanoparticles.Heterogeneous PSMA expression on circulating tumor cells: a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancerEMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression.Liquid biopsy: ready to guide therapy in advanced prostate cancer?Novel biomarkers for prostate cancer: An evidence-based review for use in clinical practice.Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer.The promise of circulating tumor cells for precision cancer therapy.Epithelial-mesenchymal transition in tumor metastasis.Changing face of the healthcare industry: what is the possible future impact on bioanalysts?
P2860
Q26744808-B8D701A7-A3F2-41F8-A8A9-5C05898FE0CCQ26747144-37C60656-2CD7-4404-B010-157A93AFC66BQ26752116-409A495D-B2A3-449A-80FC-7E85BBE7DF66Q26768470-4EF5F27C-6720-491F-84C2-2CD49B745E44Q26827815-21EF4BCC-7D96-46BC-8CA8-2F112CEC6C15Q27022113-AC4418C4-AB4B-4C0B-922E-DD17A750F1FFQ27334654-F2AA7852-FFEA-4004-AC12-B329A3C98BF3Q28070333-5CE51354-5FE6-4582-9D83-28C2D52A6426Q28078477-FAAEB1BD-E842-4C3E-BA54-C8C3BDA001BFQ28082935-95A1547C-E201-4B23-8BB4-3A9DB6F2F947Q28083261-26CDF01F-B950-4A23-B1B5-0077BFC14CB0Q30239808-9DDD6747-6522-4A52-BD64-BE2025115BF3Q30277291-2470D8C7-35F3-4CB8-9D7C-9A28C0D5754CQ34108738-73B41A28-7856-4FD1-BECD-6370B5523AB4Q34351799-7A8B9C76-0DAB-47A5-B771-AA2904A5C345Q34365632-2BDBD3AA-1E65-40F7-882F-A58D344DC58AQ34432859-F11D1E5A-BD85-4E29-B052-E5C1E478CC44Q34577724-2183457D-AE5C-4541-A756-16EF0DAD3C6CQ35543094-3601C065-680E-4AA8-B1AA-711B0DDBF4CDQ35584698-094BC78D-819D-4068-BEBD-6D11170A1BB9Q35655761-5F4CE037-F44F-4DCB-90A2-120B8A9CCBC7Q35929366-5A67FCCB-0694-4DBF-85C2-29734B5B5332Q36030759-5DFC6254-7F59-4309-A7F8-BB6DFD043004Q36362489-98AF4D90-4819-4298-B143-D8B544390189Q36407003-9FD8F8A6-0A54-4766-B6F3-4D3728B892F8Q37688197-F54C8564-8A23-46D2-AD8C-E97EFC09E305Q38232184-BC2B2148-DBC7-4544-BBA1-0EAECE5B4481Q38311282-986D6588-861D-466F-BDEB-BC4B3C6156CFQ38590310-EBCFBECF-2678-40DC-A479-CE4317CAA11DQ38678110-E99A8651-E930-473D-A1B3-60A91FF72436Q38723767-363EC7BC-BD68-4C38-81BF-6B7365B07E22Q38723987-9816BE1B-7E1F-45B6-BC12-9266946FAA71Q38773250-73347C8E-A06A-433C-93A4-55E658805AFFQ38776791-461361C6-A9A0-44B5-90EB-18A0EE5376B7Q38840458-B4C22220-DEDA-4576-9839-911884B81728Q38874800-05DD32E5-CEFC-4CFB-8BCB-54A3D7DF7AF0Q38912917-EAD1E460-B01E-4FF8-9EBD-BA959704C240Q39031157-EFFE1AF9-3305-4414-BD4B-8D84537D80F1Q39085731-1C37D4A2-6CFB-4C8A-8A6E-03A9DD7EA1AAQ39110207-E89DD909-A8D5-41BB-BF2D-32DACFEB6C8E
P2860
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Circulating tumor cell counts ...... ion-resistant prostate cancer.
@ast
Circulating tumor cell counts ...... ion-resistant prostate cancer.
@en
type
label
Circulating tumor cell counts ...... ion-resistant prostate cancer.
@ast
Circulating tumor cell counts ...... ion-resistant prostate cancer.
@en
prefLabel
Circulating tumor cell counts ...... ion-resistant prostate cancer.
@ast
Circulating tumor cell counts ...... ion-resistant prostate cancer.
@en
P2093
P2860
P356
P1476
Circulating tumor cell counts ...... tion-resistant prostate cancer
@en
P2093
Amir Goldkorn
Benjamin Ely
Catherine M Tangen
Celestia S Higano
Ian Murchie Thompson
J Paul Monk
Louis M Fink
Maha Hussain
Mark Garzotto
Michael A Carducci
P2860
P304
P356
10.1200/JCO.2013.51.7417
P407
P577
2014-03-10T00:00:00Z